Details for Patent: 10,973,870
✉ Email this page to a colleague
Which drugs does patent 10,973,870 protect, and when does it expire?
Patent 10,973,870 protects FIRMAGON and is included in one NDA.
This patent has one hundred and eight patent family members in twenty-four countries.
Summary for Patent: 10,973,870
| Title: | Methods of treating prostate cancer with GnRH antagonist |
| Abstract: | The invention provides methods and dosing regimens for safely and effectively treating androgen-dependent prostate cancer with a gonadotrophin releasing hormone (GnRH) antagonist without causing a testosterone spike and/or other side effect of GnRH agonist therapy such as a urinary tract infection, or an arthralgia-related or cardiovascular side effect. |
| Inventor(s): | Tine Kold OLESEN, Bo-Eric Persson, Per CANTOR, Egbert A. van der MEULEN, Jens-Kristian Slott JENSEN |
| Assignee: | Ferring BV |
| Application Number: | US16/851,179 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 10,973,870 |
|
Patent Claim Types: see list of patent claims | Use; |
Drugs Protected by US Patent 10,973,870
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ferring | FIRMAGON | degarelix acetate | POWDER;SUBCUTANEOUS | 022201-001 | Dec 24, 2008 | RX | Yes | No | 10,973,870 | ⤷ Start Trial | TREATMENT OF ADVANCED PROSTATE CANCER WITH A REDUCED LIKELIHOOD OF CAUSING A GONADOTROPHIN RELEASING HORMONE AGONIST SIDE-EFFECT | ⤷ Start Trial | ||||
| Ferring | FIRMAGON | degarelix acetate | POWDER;SUBCUTANEOUS | 022201-002 | Dec 24, 2008 | RX | Yes | Yes | 10,973,870 | ⤷ Start Trial | TREATMENT OF ADVANCED PROSTATE CANCER WITH A REDUCED LIKELIHOOD OF CAUSING A GONADOTROPHIN RELEASING HORMONE AGONIST SIDE-EFFECT | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 10,973,870
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| 08250703 | Feb 29, 2008 | |
International Family Members for US Patent 10,973,870
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2009213748 | ⤷ Start Trial | |||
| Australia | 2009213751 | ⤷ Start Trial | |||
| Brazil | PI0908127 | ⤷ Start Trial | |||
| Brazil | PI0908129 | ⤷ Start Trial | |||
| Canada | 2714444 | ⤷ Start Trial | |||
| Canada | 2714445 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
